Evolving strategies for targeted cancer therapy--past, present, and future.
Wells
Samuel A
SA
Nevins
Joseph R
JR
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D018276:Carcinoma, Medullary / Q000378:metabolism / Q000601:surgery*; D004273:DNA, Neoplasm / Q000032:analysis; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000068877:Imatinib Mesylate; D018813:Multiple Endocrine Neoplasia Type 2a / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D018814:Multiple Endocrine Neoplasia Type 2b / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D020411:Oligonucleotide Array Sequence Analysis; D010879:Piperazines / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000235:genetics; D051096:Proto-Oncogene Proteins c-ret; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000187:drug effects / Q000235:genetics; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000601:surgery*; D013965:Thyroidectomy
D000970:Antineoplastic Agents; D001549:Benzamides; D004273:DNA, Neoplasm; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D051096:Proto-Oncogene Proteins c-ret; D020794:Receptor Protein-Tyrosine Kinases